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ABSTRACT 
Background: Transcatheter aortic valve implantation (TAVI) has been adopted worldwide as the standard 
treatment for severe aortic stenosis in symptomatic patients at prohibitive or high surgical risk, but there are 
still several areas where consensus and evidence are lacking. The purpose was to obtain a global view of 
current practice related to TAVI with the potential to identify the main areas of consensus and divergence 
between centers. 
Methods: An online questionnaire was distributed in centers performing TAVI including a total of 58 
questions concerning pre-procedural evaluation, procedural practices and post-procedural management.  
Results: The survey was completed by 250 centers (with a cumulative experience of nearly 70,000 TAVI) 
from 38 different countries. Heart team meetings and surgical risk scores were routinely performed in most 
(>95%) centers, but frailty (44%) and quality of life (28%) assessments were less frequently performed. 
General anesthesia remained the most frequent type of anesthesia (60% of centers), and significant 
variability was detected in the examinations for residual aortic regurgitation assessment during the procedure 
and in post-procedural ECG monitoring and temporary pacemaker implementation (from none to ≥72 hrs 
post-TAVI). Dual antiplatelet therapy duration post-TAVI was highly variable  (1, 3, and ≥6 months in 14%, 
41% and 32% of centers, respectively) and lack of consensus in antithrombotic regimen was observed in 
patients with atrial fibrillation requiring anticoagulation therapy (anticoagulation alone, 
anticoagulation+aspirin, anticoagulation+clopidogrel, and triple therapy in 28%, 37%, 26% and 4% of 
centers, respectively).  
Conclusions The WRITTEN survey provided extensive data on current TAVI-related practice and identified 
important differences between centers in key aspects of pre-, intra-, and post-operative management. This 
highlights the urgent need for further studies and evidence-based data to guide multiple aspects of the TAVI 
field.  
 
Key words: TAVI; TAVR; Real World Assessment Valvular Stenosis; Web-based Survey  
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INTRODUCTION 
Transcatheter aortic valve implantation (TAVI) has been widely adopted as a standard treatment for 
symptomatic, severe aortic stenosis in patients at high or prohibitive surgical risk [1-3].
 
Increased operator 
experience, technological developments and improvements in patient selection have significantly decreased 
peri-procedural complications and improved procedural success rates and clinical outcomes [2,4,5]. To date, 
it is estimated that more than 200,000 TAVI procedures have been performed worldwide and these numbers 
are expected to increase exponentially with anticipated expansion towards treatment of intermediate and low-
risk patients [6,7].  
There remain, however, multiple areas in the TAVI field where adequate evidence-based data or 
even expert consensus recommendations are still lacking [8,9]. Thus, several issues around the patient 
selection process remain unresolved. Similarly, there are important differences in procedural approaches and 
techniques for TAVI based on local clinical practice. Finally, post-procedural management varies widely by 
center and transcatheter valve type, particularly with respect to antithrombotic therapies and management of 
conduction disturbances. Therefore, we designed the WRITTEN survey, an internet-based questionnaire, to 
investigate current practice in TAVI centers around the world and to better understand contemporary 
practices related to patient selection, main technical aspects of the procedure, and post-procedural 
management.  
 
METHODS 
Survey design 
The survey was designed by a team of interventional cardiologists (E.C., L.N-F.) and independently 
reviewed by a third physician with research experience in the TAVI field (J.R-C.). It was developed on a 
dedicated online platform (www.cardiogroup.org/TAVI/) and finally included a total of 59 questions with 
single (n=43), multiple (n=9) choice and open-ended (n=7) questions (supplementary material, online 
Table 1). The survey was designed to address five major domains related to TAVI: (i) general information 
about the TAVI program in each institution, (ii) the patient selection process, (iii) procedural techniques and 
imaging tools, (iv) post-procedural management, and (v) patient follow-up. The survey engine was built 
under supervision of one of the investigators (E.C.) using a dedicated web platform, PHP code language and 
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Oracle MySQL client as appropriate. The software allows monitoring results at all times as well as, and 
ongoing monitoring for survey accrual and completion was performed. The study was approved by the 
Ethics Committee of Hospital Clinico San Carlos, Madrid, Spain. 
Survey distribution 
At least one regional TAVI expert from each country or region was contacted and invited to distribute the 
survey locally. In addition, the survey was promoted through general interventional cardiology mailing lists, 
announcements by official societies of interventional cardiology, website advertisements 
(www.TCTMD.com), and personalized emails to TAVI operators. Invitations were distributed in different 
geographic areas simultaneously over a period of 6 months (March 2015 to September 2015). It was 
requested that only one individual from each TAVI center complete the survey on behalf of the entire heart 
team, and only one questionnaire per center was accepted. The name of each participating institution was 
recorded to avoid duplicate entries but was registered separately in the web engine and blinded during 
analysis and reporting. Participation was purely voluntary and unpaid, and all responses were kept 
completely confidential.  
Statistical Analysis 
Categorical variables were expressed as percentages and continuous variables as mean (SD) or median 
(interquartile IQR: 25-75th percentile or range: minimum-maximum) according to variable distribution. 
Comparison of qualitative variables was performed with the X
2
 test and quantitative variables were 
compared with a Student t test or Wilcoxon rank-sum test. All analyses were performed using SPSS 20 
(IBM, Armonk, NY, USA) or Prism graph pad version 6.0 (GraphPad Software, Inc. Ca, USA).  
 
RESULTS 
A total of 296 surveys were retrieved from the website. Of these, 46 (15.5%) were excluded for the following 
reasons: 32 were completely empty, 12 were significantly incomplete (less than 50% of valid answers) and 2 
were duplications. A total of 250 (84.5%) TAVI centers completed the questionnaire adequately and were 
analyzed. The centers were from 38 different countries distributed in the Mediterranean region (n=96 
centers, 38.4%), North America (n=64 centers, 25.6%), Northern and Continental Europe (n=52 centers, 
20.8%), Central and South America (n=29 centers, 11.6%), and Asia or Australia (n=9 centers, 3.6%) as 
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shown in Figure 1. The name, city and country of participating centers are listed in supplementary 
material (online Table 2). Participating centers accounted for an overall experience of 68,936 TAVI 
procedures between 2005 and 2015, with a median of 46 procedures (IQR: 21 to 100; range: 10 to 600 
procedures) in the year prior to survey completion (Table 1). Centers with a limitation on the annual number 
of TAVI procedures by their health system (n=82, 32.8%) performed a much lower number of procedures 
per year than those centers without a limitation (30 procedures/year, IQR: 16-65, versus 60 procedures/year, 
IQR: 26-128, p<0.001). The average waiting time to receive a TAVI was 1 month, ranging from 1 to 20 
months.  
Pre-procedural evaluation process 
Heart team meetings were regularly scheduled in most (97.0%) centers with a high participation of 
interventional cardiologists (96.8%), cardiac surgeons (95.6%) and general cardiologists (61.6%), but low 
involvement of other specialists (anesthesiologists: 38.0%; radiologists: 20.8%; internists/geriatricians: 
12.8%). At least one surgical risk score was used for clinical evaluation in almost all centers (99.2%), and 
137 (54.8%) centers preferred to combine 2 surgical scores (figure 2A). Frailty tests were systematically 
performed in less than half of the centers (44.5%) and were very heterogeneous in nature (more than 20 
different frailty tests were reported). Quality of life (28.2%) and 6-minute walk (21.3%) tests were rarely 
performed (figure 2B). Moderate or low risk patients (defined as STS score <8) represented up to 22% of the 
current TAVI candidates (figure 2C).  
Regarding pre-procedural imaging, cardiac computed tomography (CT) was performed in the vast 
majority of centers (94.0%) and it was considered the gold standard for aortic annulus assessment and valve 
sizing in the majority (90.3%). Transesophageal echocardiography (TEE) and femoral angiography were 
routinely performed before the TAVI procedure in 66.4% and 49.2% of the centers, respectively.  Systematic 
coronary angiography was performed pre-procedure in all centers, and concomitant severe coronary artery 
disease was usually treated before the TAVI procedure (79.6%).  Deferring treatment of severe coronary 
disease prior to TAVI was a marginal strategy (3.6%).  Physiological assessment of the severity of coronary 
artery disease with fractional flow reserve or instantaneous flow ratio was performed in 16.4% of the centers.  
In patients considered to be high risk for coronary obstruction during TAVI (low coronary artery ostia), the 
use of a coronary protection wire was the most common strategy (45.7%), followed by the selection of a self-
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expandable valve (SEV) system (27.8%). Antibiotic prophylaxis was generally administrated before TAVI in 
most centers (91.4%), but high variability was observed in the dose regimen (Table 2).  
Procedural Management 
TAVI approaches, the percentage of valve type and transcatheter valve prostheses availability in the 
participating centers are listed in Table 2. The transfemoral approach was the most frequently used access 
route (median of 84% of the procedures, IQR: 80-94%) followed by the transapical approach (median: 5.0%, 
IQR: 0-10%). Patients with adequate transfemoral access were referred for a non-transfemoral approach in 
only a small minority of centers (6.6%). A fully percutaneous approach was the preferred technique for 
gaining femoral access in 82.5% of centers, and surgical cut-down was used in 17.5% of centers. In case of a 
fully percutaneous approach, the two Perclose (Abbott Vascular, Santa Clara, California) pre-closure 
technique was the most commonly reported for femoral artery hemostasis (57.3%). Most centers (60%) used 
general anesthesia in >50% of the transfemoral procedures, and local analgesia + conscious sedation was the 
preferred anesthesia technique in 40% of centers. Regardless, an anesthesiologist assisted with the 
transfemoral and subclavian approach procedures (irrespective of the type of anesthesia) in the vast majority 
of centers (94%). Anticoagulation during the procedure was almost universally achieved with heparin 
(99.6%) and was guided by activated clotting time measurements in most centers (72.4%).  
Intra-procedural TEE guidance was systematically used in 46.2% of centers. Aortography, followed 
by hemodynamic assessment and TEE were the most common examinations used for assessing residual 
aortic regurgitation (AR) immediately following valve implantation (84.1%, 62.6% and 62.2% of centers, 
respectively) (Figure 3A). Conversely, the operators relied first on TEE (46.7%) in case of discrepancies, 
followed by aortography (25.2%) and hemodynamic assessment (18.4%) (Figure 3B). Whereas aortic 
balloon valvuloplasty was performed in most centers (84.6%) prior to valve implantation, direct implantation 
without valvuloplasty was routinely performed in 15.4% of the centers. No center used embolic protection 
devices systematically during the TAVI procedures, but 13.5% of centers reported a selective use of embolic 
protection devices.  
Post-Procedural Management 
Continuous ECG monitoring following TAVI was maintained during ≤24, ≤48 or ≥72 hours in 
21.6%, 38.6% and 39.8% of the centers, respectively. The temporary pacemaker (PM) was removed at the 
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end of the procedure in the absence of new conduction disturbances in 28.6% of the centers, but major 
differences were observed according to valve type (48.1% and 9.8% for balloon-expandable and self-
expandable valves, p=0.001, respectively) (Figure 4A). If transient atrioventricular (AV) block occurred 
during the TAVI procedure, a watchful waiting strategy (temporary PM maintenance and observation for a 
definitive indication for permanent PM implantation) was the most commonly adopted (68.8% for SEV and 
70.3% for BEV, p=0.248), but a permanent PM was implanted without further delay in 8.4% of centers 
(12.6% for SEV and 7.2% for BEV, p=0.064) (Figure 4B). The occurrence of a new left bundle branch 
block (LBBB) did not alter post-procedural management in the majority of the centers (60%). However, new 
LBBB was considered an indication for permanent PM implantation in 15.6% of centers and for extending 
maintenance of the temporary PM in 18% of centers, without differences between BEV and SEV (p=0.828) 
(figure 4C). Further investigations of new LBBB with either electrophysiological study or transcutaneous 
loop recorder was reported in only 5% of the centers.    
Dual antiplatelet therapy (DAPT) was the most common antithrombotic treatment prescribed at 
hospital discharge in patients without atrial fibrillation (AF) (89.5% of the centers), but the duration of such 
antithrombotic therapy varied widely among centers (1, 3, 6, 12 months and indefinitely in 14.3%, 43.8%, 
35.5%, 4.6% and 0.5% of centers). A minority of centers (8.8%) reported the systematic use of single 
antiplatelet therapy with aspirin alone (Figure 5A). High variability in antithrombotic regimes between 
centers was observed in patients with AF: warfarin alone, warfarin+aspirin, warfarin+clopidogrel and triple 
therapy were used in 27.9%, 38.9%, 25.9% and 4.5% of the centers, respectively (Figure 5B).  Left atrial 
appendage closure was marginally reported (<0.5%) as an alternative therapy to medical treatment. Post-
discharge, patients were followed in a dedicated TAVI clinic in only half (n=137, 56%) of the centers, and 
the interventional cardiologist was the primary physician responsible in the majority (n=123, 89.8%). In the 
absence of a TAVI clinic, both interventional (n=59, 56.7%) and general cardiologists (n=44, 42.3%) took 
care of patients’ follow-up.  
 
DISCUSSION 
We have reported the results of the first large-scale worldwide survey to describe the current 
practices in TAVI field, including patient evaluation and selection, procedural practices and post-procedural 
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management. Our main findings can be summarized as follows: 1) whereas heart team meetings (involving 
cardiologists and cardiac surgeons) and surgical risks scores were widely implemented during the patient 
selection process, the involvement of other specialists and the use of functional and frailty tests were 
infrequent; 2) with respect to pre-procedural imaging, cardiac CT scan has been nearly universally adopted 
as the gold standard for annulus assessment and valve sizing; 3) the transfemoral arterial approach was by far 
the most common access route, and only a small minority of centers treated patients with adequate 
transfemoral access by any other approach. However, a significant variability among centers was observed in 
the type of anesthesia (general vs. local), as well as in the used of imaging guidance and evaluation of 
residual AR during TAVI procedures; 4) substantial variability was also observed among centers regarding 
the duration of ECG monitoring and temporary pacing post-TAVI, in addition to significant differences 
according to valve type. However, a higher degree of agreement was observed in the management of 
conduction disturbances such as peri-procedural transient AV block or new LBBB; and 5) DAPT (aspirin + 
clopidogrel) was the most common anti-thrombotic treatment post-TAVI, but the duration of such therapy 
was highly variable (ranging from 1 to 12 months). In patients requiring anticoagulation therapy due to AF, 
the recommended antithrombotic regimen varied widely between centers.  
Pre-procedural evaluation process 
The pre-procedural evaluation process is essential in the patient selection-process and in determining 
TAVI eligibility. TAVI candidates usually have several comorbidities that may impact long-term outcomes. 
In fact, a relatively high proportion of patients fail to experience functional improvement or even die due to 
non-cardiovascular causes within the months following successful TAVI [10-12], leading to a high 
proportion of “futile” procedures [13]. The results of this survey showed that heart team meetings have been 
largely adopted across centers worldwide for the evaluation of TAVI candidates as recommended by 
guidelines [14] and the Valve Academic Research Consortium-2 (VARC) [15]. Although the true clinical 
impact of the heart team in the TAVI decision-making process has not been evaluated yet, it is generally 
accepted that team-based, individualized decision making helps to determine the optimal treatment strategy 
for each patient. However, the survey revealed that the involvement of other specialists such as imaging 
experts, anesthesiologists or geriatricians, who might contribute to this process, is highly infrequent. The 
survey demonstrated that most centers used at least one surgical risk score in the evaluation process, with the 
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STS score being the most commonly utilized. Despite the well-recognized limitations of surgical risk scores 
in the TAVI arena [16] and the demonstrated incremental value of functional, frailty and quality-of-life tests 
[10,17-24], particularly in identifying patients unlikely to benefit from the procedure [13], these additional 
tests appear to be underused in current clinical practice. The reasons for this are probably multifactorial and 
may include time constraints and organizational issues, as well as a lack of consensus regarding the best test 
for evaluating frailty (up to 20 frailty tests were reported by different centers). These findings reflect the 
importance of further research regarding the composition of the heart team and the optimal risk scores and 
ancillary evaluations to be used in the TAVI population.  
Although this survey was conducted before the publication of any randomized data on the treatment 
of moderate risk patients, up to one-fourth of the patients receiving TAVI among different centers were 
considered to be moderate-to-low risk surgical candidates. The shift towards the treatment of lower risk 
patients has spontaneously occurred together with the increasing experience of operators/centers and 
improvements in transcatheter valve technology [4,5]. The recent results of the PARTNER-II trial showing 
the non-inferiority of TAVI vs. SAVR in moderate-risk patients and TAVI superiority for those patients 
treated through the transfemoral approach provides the basis for formally recommending this treatment in 
this important group of patients [7].  
Procedural Management 
In recent years, technical developments and the improvement in complication rates have made TAVI 
a more simplified procedure. Use of the transfemoral approach has increased over the years [5] and this was 
confirmed in this survey, with up to 85% of the cases treated through this approach around the world. With 
the expansion of the technique to lower risk candidates with fewer comorbidities, we may expect a further 
increase in the rate of transfemoral procedures. Likewise, the surgical cut-down access -the standard way to 
access the femoral artery in the early TAVI era- has been replaced by a fully percutaneous approach in more 
than 80% of the centers.  
There is current controversy about the need for general anesthesia in TAVI procedures [25], and the 
results of this survey, reporting a large variability between centers in the type of anesthesia, also reflect the 
lack of consensus on this important aspect of the procedure. Future studies will have to further determine the 
potential advantages of a minimalist TAVI approach on in-hospital infections, earlier discharge, cost-saving 
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and patient comfort, without jeopardizing safety. Of note, the vast majority of centers reported the presence 
of an anesthesiologist on most of the procedures irrespective of the type of anesthesia, and this is also an 
important logistic aspect of the TAVI procedure that may need further evaluation in case of the full 
implementation of a minimalist approach. Also, the systematic use of TEE for TAVI guidance (strategy 
applied by close to half of the centers in this survey) may preclude further expansion of the minimalist 
approach. Taking into consideration that the rate of peri-procedural complications including significant AR 
is much lower with the use of newer transcatheter valve platforms [26-28], TEE may be a back-up tool in 
case of significant AR or hemodynamic instability. Notably, aortography was the most frequent examination 
used to assess residual AR, probably because of its accessibility and rapidity. However, it has the 
disadvantages of increasing the total amount of contrast and the impossibility of determining the origin of 
AR (paravalvular versus central). In fact, AR assessment continues to be challenging, but TEE was the most 
reliable tool for the evaluation of AR according to the results of this survey. In addition, hemodynamic 
evaluation has become an important AR-assessment tool used in 60% of the centers and may have 
incremental added value in case of discrepancies between imaging tests [29]. Overall, significant divergences 
between centers were observed regarding the evaluation of AR post-TAVI, one of the major factors 
determining procedural success. This highlights the need for further studies in order to establish evidenced-
based recommendations in this important procedural aspect.  
Post-Procedural Management 
The survey revealed several significant differences across centers in post-procedural management 
and follow-up. The occurrence of arrhythmias, conduction disturbances and the need for a permanent 
pacemaker after TAVI remain frequent complications and are a major concern. Whereas the majority of 
conduction disturbances and arrhythmias occur during the procedure, a significant number may also occur 
after 24 hours. Up to 72 hours of continuous rhythm monitoring after TAVI is recommended by the VARC-2 
consensus document in order to maximize detection of conduction disturbances and arrhythmias [15], which 
have an important impact on clinical short and long-term outcomes [30-32]. However, almost 60% of the 
centers reported maintaining continuous ECG monitoring for less than 48hours, which may result in the 
under-diagnosis of rhythm disturbances. 
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It is well established that the rates of both new-onset LBBB and the need for permanent pacemaker 
implantation are higher with the use of self-expandable (38-57% and 11-39%, respectively) compared to 
balloon-expandable valves (16-28% and 4-13%, respectively) [9,33]. Interestingly, whereas the survey 
revealed significant differences in the maintenance of a temporary pacemaker in the absence of new 
conduction disturbances according to valve type, the management of transient AV block during valve 
implantation and new persistent LBBB appeared to be similar between self- and balloon-expandable valves. 
The clinical impact of transient AV block during valve implantation remains unclear. The most commonly 
adopted strategy was to extend the time with a temporary PM and wait for a definitive indication of a 
permanent PM implantation. Transient damage of the AV conduction system has been previously reported 
[34] and direct permanent PM implantation in such patients may lead to a low ventricular pacing rate in the 
follow-up [35]. However, around 10% of the centers preferred to implant a permanent pacemaker in such 
patients. Similarly, the management of new LBBB has not been well defined and the survey confirmed the 
adoption of several different strategies. Although, patients with new LBBB have been shown to have a 
higher rate of permanent PM implantation during the follow-up [36-37], Ramazzina et al. reported a very 
low rate of ventricular pacing (<1%) in patients with permanent PM implantation immediately after LBBB 
occurrence, suggesting a more conservative approach in this scenario [35]. Moreover, the protective effect of 
PPM implantation after TAVI remains unclear, especially in very wide LBBB [38]. The relatively high 
proportion of patients with new LBBB, the expansion of future TAVI indications and the potential negative 
effect of LBBB justify additional investigations and rigorous ECG and clinical follow-up in this setting.  
Bleeding and ischemic events following TAVI are common, have significant deleterious clinical 
impact, and may be modifiable with the optimization of post-procedural pharmacology [39,40]. In the 
absence of an indication for therapeutic anticoagulation, DAPT with aspirin (indefinitely) and clopidogrel 
has been empirically recommended by consensus of TAVI experts [16,41]. The survey showed that this 
recommendation was followed by the vast majority of centers, but that major differences existed in the 
duration of antithrombotic therapy. Importantly, data on antithrombotic treatment post-TAVI are limited to 
observational studies and very small randomized studies (aspirin+clopidogrel) [42]. Several larger 
randomized studies are currently ongoing [41] and should provide evidence-based data with respect to the 
optimal antithrombotic therapy strategy. In addition, about one-third of patients undergoing TAVI require an 
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oral anticoagulant, typically warfarin for AF [43,44]. In this setting, the absence of consensus was even more 
evident and according to the results of this survey, the antithrombotic regimens were highly variable. The 
clinical impact of ischemic and bleeding events during follow-up highlights the difficult equilibrium in this 
elderly and high-risk population. Therefore, the optimal pharmacological or mechanical (left atrial 
appendage occlusion) therapy in patients with concomitant AF undergoing TAVI should also be tested in 
future randomized trials.  
Limitations 
The voluntary nature of this survey has inherent limitations and may have biased the results. 
However, this may have been partially compensated for by the large number of centers from different 
regions that participated in the survey. Also, the survey provided a snapshot of TAVI practices around the 
world during a brief period of time and therefore does not take into account changes in practice patterns over 
time.  
 
CONCLUSIONS 
This TAVI survey provided extensive data on current practice in the TAVI field and identified 
important differences between centers in some key aspects of pre-, intra- and post-operative management. 
Whereas a general consensus was observed on the implementation of the heart team for the patient selection 
process, the involvement of other specialists as well as frailty examinations were largely underused. With 
respect to the TAVI procedure, modes of anesthesia and the method for evaluating residual AR immediately 
after valve deployment were highly variable. Further research for obtaining evidence-based data appears 
important in order to provide consistent recommendations on these important aspects of the TAVI procedure. 
A major lack of consensus was also observed in the post-procedural management of conduction disturbances 
and antithrombotic treatment (particularly regarding duration and regimen in AF patients). These differences 
evidenced the urgent need for well-conducted studies in this field. More than 10 years after the very first 
TAVI procedure and in an era in which TAVI is expanding towards the treatment of lower risk patients, the 
current survey evidenced a large number of uncertainties and practice differences in TAVI. To date, major 
research efforts have focused on showing the safety and efficacy of this procedure compared to medical or 
surgical treatment. It is now time to obtain further evidence-based data on several peri-procedural aspects of 
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this important therapy. This should translate into a more uniform practice and may also contribute to 
improving the results of TAVI.             
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Total number of TAVI procedures in 250 centers 68,936 (18,309 in the last year)   
  n or median % or IQR 
Answered 
question 
When was the first transcatheter valve implanted in 
your institution? (year) 
2010 
 
2005-2015 (range) 
 
241 
 
How many TAVI procedures have been performed in 
your institution to date? 
161 
 
64-400 
10-2300 (range) 
238 
 
How many TAVI procedures were performed in your 
Institution last year? (number): 
46 
 
21-100 
10-600 (range) 
239 
 
Does your local or central health care system place an 
annual limit on the number of TAVI you can perform     
250 
 
Yes 82 32.8   
No 168 67.2   
if yes, specify numbers per year 38 20-65   
How long is your average patient waiting time to 
receive a TAVI? (months) 
1 
 
1-2 
 
245 
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Approach and procedural management Centers 
Approaches available (n=250)   
Transfemoral  248 (99.2) 
Transapical 174 (69.6) 
Transaortic 143 (57.2) 
Subclavian 97 (38.8) 
Transcarotid 27 (10.8) 
Other 15 (6.0) 
Approach selection criteria (n=242)  
If ilio-femoral access is adequate, all patients are referred for a 
transfemoral approach 
226 (93.4) 
Some TAVI candidates are referred for non-transfemoral approach 
even if ilio-femoral arteries are adequate 
14 (5.8) 
Most TAVI candidates are referred for non-transfemoral approach 
even if ilio-femoral arteries are adequate 
2 (0.8) 
Percentage of valve type (n=231)  
Balloon-expandable valve 65 (30-90) 
Self-expandable valve 40 (15-80) 
Prosthesis available (n=250)  
Edwards valve  205 (82.0) 
Corevalve system 199 (79.6) 
Lotus valve 57 (22.8) 
Direct Flow  34 (13.6) 
Portico 28 (11.2) 
Acurate Symetis 12 (4.8) 
Jena Valve 11 (4.4) 
Engager 8 (3.2) 
Others 5 (2.0) 
Anesthesia Regimen (n=248)   
100% General Anesthesia 98 (39.5) 
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>50% General Anesthesia 149 (60.1) 
≥50% Local Anesthesia 99 (39.9) 
100% Local Anesthesia 26 (10.5) 
Antibiotic Prophylaxis (n=244)   
None 21 (8.6) 
Only 1 dose before TAVI 113 (46.3) 
1 dose before and 1 dose after 3 (1.2) 
1 dose before and 2 doses after 106 (43.4) 
1 dose before and 3 doses after 1 (0.4) 
Values are n (%) or median, (IQR). 
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